312 related articles for article (PubMed ID: 34393832)
21. The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics.
Ridlon JM; Bajaj JS
Acta Pharm Sin B; 2015 Mar; 5(2):99-105. PubMed ID: 26579434
[TBL] [Abstract][Full Text] [Related]
22. A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings.
Voronova V; Sokolov V; Al-Khaifi A; Straniero S; Kumar C; Peskov K; Helmlinger G; Rudling M; Angelin B
Cell Mol Gastroenterol Hepatol; 2020; 10(1):149-170. PubMed ID: 32112828
[TBL] [Abstract][Full Text] [Related]
23. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
24. TGR5 signaling mitigates parenteral nutrition-associated liver disease.
Willis KA; Gomes CK; Rao P; Micic D; Moran ER; Stephenson E; Puchowicz M; Al Abdallah Q; Mims TS; Gosain A; Yin D; Talati AJ; Chang EB; Han JC; Pierre JF
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G322-G335. PubMed ID: 31905022
[TBL] [Abstract][Full Text] [Related]
25. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein.
Kok T; Hulzebos CV; Wolters H; Havinga R; Agellon LB; Stellaard F; Shan B; Schwarz M; Kuipers F
J Biol Chem; 2003 Oct; 278(43):41930-7. PubMed ID: 12917447
[TBL] [Abstract][Full Text] [Related]
26. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
[TBL] [Abstract][Full Text] [Related]
27. Chenodeoxycholic Acid: An Update on Its Therapeutic Applications.
Fiorucci S; Distrutti E
Handb Exp Pharmacol; 2019; 256():265-282. PubMed ID: 31267167
[TBL] [Abstract][Full Text] [Related]
28. Role of farnesoid X receptor in cholestasis.
Yuan ZQ; Li KW
J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832
[TBL] [Abstract][Full Text] [Related]
29. Role of farnesoid X receptor and bile acids in alcoholic liver disease.
Manley S; Ding W
Acta Pharm Sin B; 2015 Mar; 5(2):158-67. PubMed ID: 26579442
[TBL] [Abstract][Full Text] [Related]
30. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.
Zollner G; Wagner M; Moustafa T; Fickert P; Silbert D; Gumhold J; Fuchsbichler A; Halilbasic E; Denk H; Marschall HU; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G923-32. PubMed ID: 16357057
[TBL] [Abstract][Full Text] [Related]
31. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
32. Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy.
Nakamura K; Yoneda M; Kimura A; Tamori K; Yokohama S; Sato Y; Kato T; Hasegawa T; Saito H; Aoshima M; Fujita M; Makino I
J Gastroenterol Hepatol; 1996 Apr; 11(4):385-90. PubMed ID: 8713707
[TBL] [Abstract][Full Text] [Related]
33. Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration.
Li G; L Guo G
Acta Pharm Sin B; 2015 Mar; 5(2):93-8. PubMed ID: 26579433
[TBL] [Abstract][Full Text] [Related]
34. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
[TBL] [Abstract][Full Text] [Related]
35. Bile acid nuclear receptor FXR and digestive system diseases.
Ding L; Yang L; Wang Z; Huang W
Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
[TBL] [Abstract][Full Text] [Related]
36. The gut microbiome-bile acid axis in hepatocarcinogenesis.
Wu L; Feng J; Li J; Yu Q; Ji J; Wu J; Dai W; Guo C
Biomed Pharmacother; 2021 Jan; 133():111036. PubMed ID: 33378947
[TBL] [Abstract][Full Text] [Related]
37. Quantitative profiling of 19 bile acids in rat plasma, liver, bile and different intestinal section contents to investigate bile acid homeostasis and the application of temporal variation of endogenous bile acids.
Yang T; Shu T; Liu G; Mei H; Zhu X; Huang X; Zhang L; Jiang Z
J Steroid Biochem Mol Biol; 2017 Sep; 172():69-78. PubMed ID: 28583875
[TBL] [Abstract][Full Text] [Related]
38. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids.
Ferrebee CB; Dawson PA
Acta Pharm Sin B; 2015 Mar; 5(2):129-34. PubMed ID: 26579438
[TBL] [Abstract][Full Text] [Related]
39. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
40. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
